DLBCL – Does the Molecular Classification Really Inform Therapy?
Description
Upon viewing this session, you will be able to:
• Assess data from recent randomized studies in DLBCL that have targeted cell of origin.
• Determine which patients with DLBCL are most likely to benefit from novel agents targeting molecular subtypes of DLBCL.
• Review perspectives regarding next steps in investigating how molecular biology of DLBCL could inform personalized therapy.
• Assess data from recent randomized studies in DLBCL that have targeted cell of origin.
• Determine which patients with DLBCL are most likely to benefit from novel agents targeting molecular subtypes of DLBCL.
• Review perspectives regarding next steps in investigating how molecular biology of DLBCL could inform personalized therapy.
Presenters
- Kieron Dunleavy, MD, George Washington University
Pricing
| Member Type | Price |
|---|---|
| List Price | $30.00 |
| Active, International, Emeritus, and Honorary Members | $20.00 |
| Associate, International Associate, Student, and Resident Members | $20.00 |
ASH Meeting on Hematologic Malignancies
Hear the latest developments in clinical care, and get answers to your most challenging patient care questions.
Learn more
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
Copyright © 2021 by American Society of Hematology